Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
Dow
Baxter
Merck

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,896,478

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,896,478
Title:Antibody purification by cation exchange chromatography
Abstract: A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity.
Inventor(s): Lebreton; Benedicte Andree (San Francisco, CA), O\'Connor; Deborah Ann (San Carlos, CA), Safta; Aurelia (Walnut Creek, CA), Sharma; Mandakini (Sunnyvale, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA)
Application Number:14/531,880
Patent Claims:1. A method for purifying rituximab from a composition comprising the rituximab and one or more contaminants selected from the group consisting of Chinese Hamster Ovary Proteins (CHOP), leached protein A, DNA, and aggregated rituximab, which method comprises the sequential steps of: (a) loading the composition onto a cation exchange material wherein the composition is at a pH from about 4.0 to about 6.0; (b) washing the cation exchange material with a first wash buffer at a pH from about 6.8 to about 9.0 and a conductivity of 0.1 to 3 mS/cm; (c) washing the cation exchange material with a second wash buffer at a pH from about 5.0 to about 6.0; and (d) eluting the rituximab from the cation exchange material using an elution buffer with a pH from about 5.0 to about 6.0 and a conductivity from about 10 mS/cm to about 100 mS/cm.

2. The method of claim 1 wherein the elution buffer comprises about 100 to about 300 mM NaCl.

3. The method of claim 1 wherein the pH of the second wash buffer and the pH of the elution buffer are approximately the same.

4. The method of claim 1 wherein the cation exchange material comprises crosslinked poly(styrene-divinylbenzene) flow-through particles coated with a polyhydroxylated polymer functionalized with sulfopropyl groups.

5. The method of claim 1 further comprising subjecting the composition comprising rituximab to one or more further purification steps either before, during, or after steps (a) through (d) so as to obtain a homogeneous preparation of the rituximab.

6. The method of claim 5 further comprising conjugating the purified rituximab wits a heterologous molecule.

7. The method of claim 5 further comprising preparing a pharmaceutical composition by combining the homogeneous preparation of the rituximab with a pharmaceutically acceptable carrier.

8. A method for purifying bevacizumab from a composition comprising the bevacizumab and one or more contaminants selected from the group consisting of a cell culture media component, garamycin, Chinese Hamster Ovary Proteins (CHOP), DNA, viral contaminant, and aggregated bevacizumab, which method comprises the sequential steps of: (a) loading the composition onto a cation exchange material wherein the composition is at a pH from about 4.0 to about 6.0; (b) washing the cation exchange material with a first wash buffer at a pH from about 6.8 to about 8.0 and a conductivity of 0.1 to 3 mS/cm; (c) washing the cation exchange material with a second wash buffer at a pH from about 5.0 to about 6.0; and (d) eluting the bevacizumab from the cation exchange material using an elution buffer with a pH from about 5.0 to about 6.0 and a conductivity from about 10 mS/cm to about 100 mS/cm.

9. The method of claim 8 wherein the elution buffer comprises about 100 to about 300 mM NaCl.

10. The method of claim 8 wherein the pH of the second wash buffer and the pH of the elution buffer are approximately the same.

11. The method of claim 8 wherein the cation exchange material comprises crosslinked poly(styrene-divinylbenzene) flow-through particles coated with a polyhydroxylated polymer functionalized with sulfopropyl groups.

12. The method of claim 8 further comprising subjecting the composition comprising the bevacizumab to one or more further purification steps either before, during, or after steps (a) through (d) so as to obtain a homogeneous preparation of the bevacizumab.

13. The method of claim 12 further comprising conjugating the purified bevacizumab with a heterologous molecule.

14. The method of claim 12 further comprising preparing a pharmaceutical composition by combining the homogeneous preparation of the bevacizumab with a pharmaceutically acceptable carrier.

Details for Patent 9,896,478

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial GENENTECH, INC. (South San Francisco, CA) 2027-10-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial GENENTECH, INC. (South San Francisco, CA) 2027-10-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial GENENTECH, INC. (South San Francisco, CA) 2027-10-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Johnson and Johnson
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.